Anna Sakura

Research field (1)： Tumor biology

Research theme for competitive and other funds (2)：

2020 - 2023 多くの癌での予後不良因子PLK1の過剰発現とPARP阻害剤とDNA損傷修復の関係
2016 - 2020 A functional analysis of NFkB downregulation due to BRCA1 inhibition

Papers (7)：

Keiko Oda-Kawashima, Anna S Sedukhina, Naoki Okamoto, Mariya Lytvyn, Kimino Minagawa, Teppei Iwata, Toshio Kumai, Eri Sato, Eiichi Inada, Ayako Yamaura, et al. NF-kB signaling in cardiomyocytes is inhibited by sevoflurane and promoted by propofol. FEBS open bio. 2020
Hidekazu Yoshie, Anna S. Sedukhina, Kimino Minagawa, Keiko Oda, Shigeko Ohnuma, Nobuyuki Yanagisawa, Ichiro Maeda, Masayuki Takagi, Hiroya Kudo, Ryuto Nakazawa, et al. A bioinformatics-to-clinic sequential approach to analysis of prostate cancer biomarkers using TCGA datasets and clinical samples: A new method for precision oncology?. Oncotarget. 2017. 8. 59. 99601-99611
Satoi Nagasawa, Anna S. Sedukhina, Yuko Nakagawa, Ichiro Maeda, Manabu Kubota, Shigeko Ohnuma, Koichiro Tsugawa, Tomohiko Ohta, Marta Roche-Molina, Juan A. Bernal, et al. LSD1 Overexpression Is Associated with Poor Prognosis in Basal-Like Breast Cancer, and Sensitivity to PARP Inhibition. PLOS ONE. 2015. 10. 2. e0118002
Yuko Nakagawa, Anna S. Sedukhina, Naoki Okamoto, Satoi Nagasawa, Nao Suzuki, Tomohiko Ohta, Hiroyoshi Hattori, Marta Roche-Molina, Ana J. Narvaez, Anand D. Jeyasekharan, et al. NF-kappa B signaling mediates acquired resistance after PARP inhibition. ONCOTARGET. 2015. 6. 6. 3825-3839
Ko Sato, Elayanambi Sundaramoorthy, Eeson Rajendra, Hiroyoshi Hattori, Anand D. Jeyasekharan, Nabieh Ayoub, Ralph Schiess, Ruedi Aebersold, Hiroyuki Nishikawa, Anna S. Sedukhina, et al. A DNA-Damage Selective Role for BRCA1 E3 Ligase in Claspin Ubiquitylation, CHK1 Activation, and DNA Repair. CURRENT BIOLOGY. 2012. 22. 18. 1659-1666

ｍore...

MISC (15)：

ｍore...

Patents (1)：

LSD1の過剰発現またはLSD1をコードする遺伝子の増幅を伴う悪性腫瘍を予防または治療するための医薬および予後予測用の乳癌組織検査キット

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page